Generex Biotechnology Provides 2019 Year-End Summary & 2020 Plans


You May Also Like

Cyclacel Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference

BERKELEY HEIGHTS, N.J., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ...

Orion intents to start an open label extension study to the REFALS phase 3 trial studying the effect of oral levosimendan in patients with ALS

Orion Corporation                            Press release       4 February 2019 at 10.00 a.m. EET Orion intents to start ...